Daniel Olson, MD, discusses the results of a phase 1 trial of brenetasfusp, a PRAME ImmTAC therapy in advanced melanoma.
Daniel Olson, MD
Advertisement
Articles by Daniel Olson, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
3
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
4
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
5